Wednesday, May 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

RFP – Nonhuman Primate Virology Laboratory for AIDS Vaccine Research

by Global Biodefense Staff
February 6, 2017
HIV particles infecting a human H9 T-cell

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking proposals from organizations capable of conducting quantitative viral RNA measurements for assessment of HIV/SIV vaccine efficacy in preclinical studies with nonhuman primates.

NIAID provides immunological and virological support for nonhuman primate studies conducted at NIAID’s Simian Vaccine Evaluation Unit (SVEU) contract sites and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development, previously called the NHP “Core Laboratories.”

The objective of the Core Laboratories has been to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines.

Advanced BioScience Laboratories, Inc. holds the current contract for the Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development (HHSN272201100022C).

The purpose of the proposed contract is to provide a NHP virology laboratory that will conduct quantitative viral RNA measurements in support of studies that evaluate prototype AIDS vaccines in nonhuman primates.

The contract will support the conduct, improvement, and development of assays designed to measure viral RNA loads in nonhuman primates that have been immunized with candidate HIV or SIV vaccines and challenged with SIV or SHIV in studies conducted at DAIDS Simian Vaccine Evaluation Unit contract sites or by NIH-supported investigators.

It is anticipated that one cost reimbursement, term type contract will be awarded for a 1-year Base period plus six 1-year options for a possible total period of performance of 7 years beginning on or about December 29, 2017.

Further details are available via Solicitation Number: NIAID-DAIDS-NIHAI2016075. The response deadline is February 15, 2017.

Tags: HIVNon-Human PrimateRequest for ProposalsVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC